DBV Technologies SA (DBVT) Lifted to Hold at Zacks Investment Research
DBV Technologies SA (NASDAQ:DBVT) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday.
According to Zacks, “DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. “
Several other brokerages have also recently weighed in on DBVT. JMP Securities assumed coverage on shares of DBV Technologies SA in a research note on Monday, September 26th. They set an “outperform” rating and a $47.00 price target on the stock. Leerink Swann restated a “buy” rating and set a $54.00 target price on shares of DBV Technologies SA in a research note on Tuesday, August 23rd. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. DBV Technologies SA has a consensus rating of “Buy” and a consensus price target of $49.57.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/18/dbv-technologies-sa-dbvt-lifted-to-hold-at-zacks-investment-research.html
DBV Technologies SA (NASDAQ:DBVT) traded up 2.11% during mid-day trading on Tuesday, reaching $36.28. 48,818 shares of the company’s stock traded hands. The firm’s 50-day moving average price is $36.04 and its 200 day moving average price is $33.79. The firm’s market cap is $1.67 billion. DBV Technologies SA has a one year low of $22.55 and a one year high of $37.98.
A number of hedge funds have recently made changes to their positions in DBVT. Deerfield Management Co. increased its stake in shares of DBV Technologies SA by 77.1% in the first quarter. Deerfield Management Co. now owns 817,806 shares of the company’s stock worth $26,620,000 after buying an additional 355,937 shares in the last quarter. JPMorgan Chase & Co. increased its stake in shares of DBV Technologies SA by 6.6% in the second quarter. JPMorgan Chase & Co. now owns 254,492 shares of the company’s stock worth $8,301,000 after buying an additional 15,849 shares in the last quarter. DekaBank Deutsche Girozentrale increased its stake in shares of DBV Technologies SA by 12.1% in the second quarter. DekaBank Deutsche Girozentrale now owns 11,100 shares of the company’s stock worth $360,000 after buying an additional 1,200 shares in the last quarter. GW&K Investment Management LLC increased its stake in shares of DBV Technologies SA by 13.7% in the second quarter. GW&K Investment Management LLC now owns 124,872 shares of the company’s stock worth $4,073,000 after buying an additional 15,034 shares in the last quarter. Finally, Sabby Management LLC increased its stake in shares of DBV Technologies SA by 50.3% in the first quarter. Sabby Management LLC now owns 70,000 shares of the company’s stock worth $2,279,000 after buying an additional 23,413 shares in the last quarter. Institutional investors own 47.92% of the company’s stock.
About DBV Technologies SA
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DBV Technologies SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies SA and related companies with MarketBeat.com's FREE daily email newsletter.